https://scholars.lib.ntu.edu.tw/handle/123456789/544325
標題: | Levels of plasma selenium and urinary total arsenic interact to affect the risk for prostate cancer | 作者: | Hsueh Y.-M. Su C.-T. Shiue H.-S. Chen W.-J. YEONG-SHIAU PU Lin Y.-C. Tsai C.-S. CHAO-YUAN HUANG |
公開日期: | 2017 | 出版社: | Elsevier Ltd | 卷: | 107 | 起(迄)頁: | 167-175 | 來源出版物: | Food and Chemical Toxicology | 摘要: | This study investigated whether plasma selenium levels modified the risk for prostate cancer (PC) related to arsenic exposure. We conducted a case-control study that included 318 PC patients and 318 age-matched, healthy control subjects. Urinary arsenic profiles were examined using HPLC-HG-AAS and plasma selenium levels were measured by ICP-MS. We found that plasma selenium levels displayed a significant dose-dependent inverse association with PC. The odds ratio (OR) and 95% confidence interval (CI) for PC was 0.07 (0.04–0.13) among participants with a plasma selenium level >28.06 μg/dL vs. ?19.13 μg/dL. A multivariate analysis showed that participants with a urinary total arsenic concentration >29.28 μg/L had a significantly higher OR (1.75, 1.06–2.89) for PC than participants with ?29.89 μg/L. The combined presence of a low plasma selenium level and a high urinary total arsenic concentration exponentially increased the OR for PC, and additively interacted with PSA at levels ?20 ng/mL. This is the first epidemiological study to examine the combined effects of plasma selenium and urinary total arsenic levels on the OR for PC. Our data suggest a low plasma selenium level coupled with a high urinary total arsenic concentration creates a significant risk for aggressive PC. ? 2017 Elsevier Ltd |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85021454128&doi=10.1016%2fj.fct.2017.06.031&partnerID=40&md5=190bcfe2abe579d2ece621640d4bd330 https://scholars.lib.ntu.edu.tw/handle/123456789/544325 |
ISSN: | 0278-6915 | DOI: | 10.1016/j.fct.2017.06.031 | SDG/關鍵字: | arsenic; selenium; arsenic; selenium; aged; arsenic urine level; Article; cancer inhibition; cancer risk; case control study; controlled study; high performance liquid chromatography; human; informed consent; limit of detection; limit of quantitation; major clinical study; male; mass spectrometry; prostate cancer; selenium blood level; urine level; blood; Prostatic Neoplasms; urine; Aged; Arsenic; Case-Control Studies; Humans; Male; Prostatic Neoplasms; Selenium |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。